RSV vaccine's star falls further following FDA setback

11 June 2019

2019_vials_production_manufacturing_biotech_big

Hopes for Novavax’ (Nasdaq: NVAX) once highly-anticipated respiratory syncytial virus (RSV) shot, ResVax, were dealt a new blow on Monday, as the US regulator said an additional Phase III trial would be needed.

With research funded by an $89.1 million grant from the Bill & Melinda Gates Foundation, Novavax has been in discussions with the US Food and Drug Administration in relation to data from the Phase III Prepare trial.

In February 2019, the firm’s share price plummeted after it said the trial did not meet its primary objective of prevention of medically significant RSV lower respiratory tract infection (LRTI).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK